Indivior Pharmaceuticals (INDV) Asset Utilization Ratio (2025 - 2026)
Indivior Pharmaceuticals' (INDV) quarterly Asset Utilization Ratio came in at 1.08 in Q1 2026, up 23.72% year-on-year from 0.87 in Q1 2025, and up 13.62% quarter-over-quarter from 0.95 in Q4 2025.
Indivior Pharmaceuticals (INDV) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 1.08 for Q1 2026.
- On a quarterly basis, Asset Utilization Ratio rose 23.72% year-over-year to 1.08 in Q1 2026; TTM through Mar 2026 was 1.08, a 23.72% increase from a year earlier, with the FY2025 full-year figure at 0.98, up 27.37% from the prior year.
- Asset Utilization Ratio improved to 1.08 in Q1 2026 per INDV's latest filing, from 0.95 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.08 in Q1 2026 and bottomed at 0.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | Indivior Pharmaceuticals | 1.00 Bn | 829.65 Mn | 277.00 Mn | 1.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 |
| Dec 31, 2025 | 0.95 |
| Sep 30, 2025 | 0.82 |
| Jun 30, 2025 | 0.83 |
| Mar 31, 2025 | 0.87 |